CRISPR Therapeutics AG (NASDAQ: CRSP) trades at approximately $59.52 per share. The clinical-stage gene editing biopharmaceutical company's equity moves within an active 52-week trading range spanning from a lower support level of roughly $44.12 up to a peak of $78.48, backed by a market capitalization of approximately $5.75 billion. Investors track its valuation closely through clinical trials and regulatory commercial milestones for its advanced CRISPR/Cas9 gene-editing therapies.